Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

13 Oct 2010 07:00

RNS Number : 2488U
Omega Diagnostics Group PLC
13 October 2010
 



 

13 October 2010 AIM: ODX 

 

Omega Diagnostics Group Plc

("Omega")

 

Trading Update

 

Omega, the AIM listed medical diagnostics company announces the following trading update for the six months to 30 September 2010 in advance of releasing its interim results on 26 November 2010.

 

Trading remains in line with management expectations with turnover approximately 15% ahead of the comparative period last year at £3.3 million (2009: £2.87 million). Sales of Genarrayt™ systems and Food Detective™ kits have grown strongly.

 

Genarrayt™

Sales of Genarrayt™ kits and instrument packages have increased substantially in the period by approximately 72% to £761k (2009: £443k). A further 22 system installations have occurred during this period in Brazil, Hungary, India, Israel, Italy, Malaysia, Syria, Thailand, Turkey and UAE bringing the total installed base around the world to approximately 80 systems since launch. We are seeing increased traction of reagent sales from these installations. Reagent sales alone were £632k (2009: £376k) in the period and we expect further progress in sales of reagent kits in the second half following this year's new system installations.

 

Food Detective™

Sales of the macroarray-based Food Detective™ have continued to perform well with volume growth particularly in the Middle East and Far East. Overall, sales of 19,225 kits have been achieved in the first half of this year (2009: 14,957 kits) providing revenues of £369k (2009: £348k). Volume growth has outstripped revenue growth due to the supply of bulk components to a customer in China who then assembles the kits locally. Food Detective™ is now available in over 40 countries.

 

The continued growth of both of these products in the second half of the year will be key. The Directors remain confident in the Group's growth prospects and trading remains in line with management expectations. Alongside the Group's organic growth we have continued to investigate acquisition opportunities.

 

 

Further enquiries:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

Kieron Harbinson, Group Finance Director

www.omegadiagnostics.com

Cenkos Securities plc

Tel: 020 7397 8900

Ian Soanes

Elizabeth Bowman

Walbrook PR Limited

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMMMGGZVGGZM
Date   Source Headline
22nd Oct 20197:00 amRNSTrading Update and Notice of Interim Results
15th Oct 20192:29 pmRNSHolding(s) in Company
14th Oct 20198:18 amRNSHolding(s) in Company
14th Oct 20197:00 amRNSHolding(s) in Company
11th Oct 20198:00 amRNSHolding(s) in Company
10th Oct 201910:30 amRNSResult of General Meeting
27th Sep 201910:00 amRNSNotice of AGM and posting of annual report
23rd Sep 20197:01 amRNSPlacing & Subscription, Notice of General Meeting
23rd Sep 20197:00 amRNSFinal Results
16th Sep 20197:00 amRNSUpdate on VISITECT® CD4 Advanced Disease
10th Sep 20197:00 amRNSPurchase Order for Chinese Food Detective® test
20th Aug 20197:00 amRNSFirst VISITECT® CD4 Advanced Disease Test Order
16th Aug 201911:00 amRNSRe. Results, Trading Update & Nigerian CD4 Order
8th Aug 20197:00 amRNSInvestor Briefing
6th Jun 20197:00 amRNSAnnouncement of Results
5th Jun 20191:37 pmRNSHolding(s) in Company
3rd Jun 20191:43 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription to raise c.£635,000
17th Apr 20197:00 amRNSTrading Update
18th Mar 20197:00 amRNSCE-Mark for VISITECT® CD4 Advanced Disease test
6th Mar 20197:00 amRNSVISITECT® CD4 update
1st Mar 20197:00 amRNSBoard Appointment
29th Jan 20197:00 amRNSVISITECT® CD4 Advanced Disease test update
10th Dec 20189:00 amRNSDirectorate Change
3rd Dec 20187:00 amRNSInterim results
19th Oct 20184:27 pmRNSHolding(s) in Company
10th Oct 20187:00 amRNSTrading Update and Notice of Interim Results
8th Oct 20182:38 pmRNSHolding(s) in Company
27th Sep 20187:00 amRNSAllergy CE-Mark and first Purchase Order
14th Sep 201811:25 amRNSResult of AGM
10th Sep 20188:56 amRNSHolding(s) in Company
6th Aug 20187:01 amRNSFinal Results
6th Aug 20187:00 amRNSVISITECT® CD4 Advanced Disease Development Update
30th Jul 20185:29 pmRNSHolding(s) in Company
18th Jul 20187:00 amRNSVISITECT® CD4 commercialisation update
12th Jul 20187:00 amRNSInvestor results presentation
2nd Jul 20187:00 amRNSNotice of Results
28th Jun 20187:00 amRNSDisposal of infectious disease business
21st May 20187:00 amRNSVISITECT CD4 development update
8th May 20187:00 amRNSAllersys? CE-Mark
2nd May 20187:41 amRNSClosure of Omega Diagnostics GmbH
24th Apr 20185:04 pmRNSPDMR Dealing
24th Apr 20187:00 amRNSHolding(s) in Company
23rd Apr 20183:50 pmRNSHolding(s) in Company
23rd Apr 20182:24 pmRNSDirector/PDMR Shareholding
23rd Apr 20182:22 pmRNSHolding(s) in Company
23rd Apr 20189:31 amRNSDirector/PDMR Shareholding
20th Apr 20187:00 amRNSAllersys Distribution Agreement
19th Apr 201811:45 amRNSInvestor Evening
10th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.